Literature DB >> 268229

Prolonged remission maintenance in acute myeloid leukaemia.

A S Spiers, J M Goldman, D Catovsky, C Costello, D A Galton, C S Pitcher.   

Abstract

Twenty-five patients with acute myeloid leukaemia were treated with three quadruple drug combinations in predetermined rotation: TRAP (thioguanine, daunorubicin, cytarabine, prednisolone); COAP (cyclophosphamide, vincristine, cytarabine, prednisolone); and POMP (prednisolone, vincristine, methotrexate, mercaptopurine). Fifteen patients (60%) achieved complete remission and five (20%) partial remission. For maintenance, five-day courses of drugs were administered every 14 to 21 days and doses were increased to tolerance. The median length of complete remission was 66 weeks. In eight patients remission maintenance treatment was discontinued and some remained in complete remission for over two years. In this series the remission induction rate was comparable with that reported for other regimens and complete remission lasted longer with this intensive maintenance regimen than with others. Nevertheless, the TRAP programme must still be regarded as only palliative treatment for acute myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 268229      PMCID: PMC1631479          DOI: 10.1136/bmj.2.6086.544

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  15 in total

1.  Treatment of the acute leukemias.

Authors:  J Bernard; C Jacquillat; M Weil
Journal:  Semin Hematol       Date:  1972-04       Impact factor: 3.851

2.  Daunorubicin in the treatment of acute myelocytic leukaemia.

Authors:  M Boiron; M Weil; C Jacquillat; J Tanzer; D Levy; C Sultan; J Bernard
Journal:  Lancet       Date:  1969-02-15       Impact factor: 79.321

3.  Acute myelocytic leukemia in adults.

Authors:  B D Clarkson
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

4.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

5.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

6.  Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.

Authors:  J U Gutterman; E M Hersh; V Rodriguez; K B McCredie; G Mavligit; R Reed; M A Burgess; T Smith; E Gehan; G P Bodey; E J Freireich
Journal:  Lancet       Date:  1974-12-14       Impact factor: 79.321

7.  Quality and quantity of survival in acute myeloid leukaemia.

Authors:  P S Burge; T A Prankerd; J D Richards; M Sare; D S Thompson; P Wright
Journal:  Lancet       Date:  1975-10-04       Impact factor: 79.321

8.  Adult acute leukemia. The Rochester (NY) Experience.

Authors:  R E Enck; A W Bauman; J M Bennett
Journal:  Arch Intern Med       Date:  1976-11

9.  Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.

Authors:  D Crowther; C J Bateman; C P Vartan; J M Whitehouse; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1970-11-28

10.  Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.

Authors:  R L Powles; J Russell; T A Lister; T Oliver; J M Whitehouse; J Malpas; B Chapuis; D Crowther; P Alexander
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more
  4 in total

1.  Cancer chemotherapy.

Authors:  R J Wrighton
Journal:  J R Soc Med       Date:  1979-01       Impact factor: 5.344

2.  Remission-induction regimens in acute nonlymphocytic leukemia.

Authors:  D C Brennan; J P Lewis
Journal:  West J Med       Date:  1980-10

Review 3.  Acute myeloid leukaemia-A review of sixty-seven cases.

Authors:  U O'Callaghan; D McCarthy; J Hegarty; F Goodwin; J J Fennelly; L G O'Connell
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

4.  Chemotherapy of acute myeloid leukaemia in adults: Medical Research Council.

Authors: 
Journal:  Br J Cancer       Date:  1979-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.